ExLibris header image
SFX Logo
Title: Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Source:

Blood [0006-4971] Furman, Richard yr:2014


Collapse list of basic services Basic
Sorry, no full text available...
Please use the document delivery service (see below)  
Holding information
Holdings in library search engine ALBERT GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Anonymous. "FDA reports increase of adverse events with Zydelig, six trials stopped." HEM/ONC today 17.8 (2016): 88-. Link to SFX for this item
2. Markham, A. "Idelalisib: first global approval." Drugs 74.14 (2014): 1701-7. Link to SFX for this item
3. Miller, Barry W. "FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma." Clinical cancer research 21.7 (2015): 1525-9. Link to SFX for this item
4. Vanhaesebroeck, B. "PI3Kδ inhibition hits a sensitive spot in B cell malignancies." Cancer cell 25.3 (2014): 269-271. Link to SFX for this item
5. "Modern Pharmaceutics, 4th Rev. Ed.(Book Review)(Brief Article)." Scitech book news 26 (2002): 109-. Link to SFX for this item
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.